Executive Team

The AVEO Oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise, and a proven track record for success in bringing important new therapies to patients.

  • Michael P. Bailey


    Michael P. Bailey

    Michael P. Bailey serves as president and chief executive officer of AVEO and a member of the company’s board of directors, bringing more than 20 years of experience in the pharmaceutical industry to the company. He joined AVEO in 2010 as the company’s chief commercial officer, was named chief business officer in 2013 and assumed his current roles in January 2015. Mr. Bailey joined AVEO from Synta Pharmaceuticals, where he served as senior vice president, business development, and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone Systems' (now Eli Lilly) Worldwide Commercial Organization. During his nine year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA® (ramucirumab) and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global commercial partnership teams. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beecham's Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at University of Notre Dame.

  • Michael N. Needle, M.D.


    Michael N. Needle, M.D.

    Michael N. Needle, M.D., serves as chief medical officer of AVEO, and brings more than 15 years of pharmaceutical industry experience in drug development and regulatory affairs. This includes central roles in the development of oncology and hematology drugs, including Erbitux® (cetuximab), Revlimid® (lenalidomide) and Pomalyst® (Pomalidomide). He most recently served as the Chief Medical Officer of Array BioPharma. Prior to Array, Dr. Needle was Chief Medical Officer of the Multiple Myeloma Research Foundation and Consortium (MMRF). Prior to MMRF, he held multiple Vice President level positions at Celgene in Clinical Research and Development in Oncology, Strategic Medical Business Development, and Pediatric Strategy. Dr. Needle also served as the Vice President of Clinical Affairs at ImClone Systems Incorporated. Dr. Needle did his fellowship in Pediatric Hematology / Oncology at the Children's Hospital Medical Center and the Fred Hutchinson Cancer Research Center of the University of Washington in Seattle and the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Needle has held faculty positions at the University of Pennsylvania and Columbia University. Dr. Needle graduated from Binghamton University with a Bachelor of Arts in Physics and received his medical degree from SUNY Downstate Medical Center, in Brooklyn, New York.

  • Matthew Dallas


    Matthew Dallas

    Mr. Dallas brings to AVEO more than 20 years of financial management experience, including 18 years in the life sciences industry. Most recently, he served as Chief Financial Officer and Treasurer of CoLucid Pharmaceuticals, a position he held through that biopharmaceutical company’s initial public offering, follow-on offering, and subsequent acquisition, for approximately $960 million, by Eli Lilly and Company in March 2017. Prior to CoLucid, Mr. Dallas served as Vice President of Finance and Treasurer at AVEO from 2011 to 2015, a period during which the Company was first preparing for the potential launch of tivozanib. He previously worked at Genzyme Corporation, NEN Life Sciences, and Kimberly-Clark Corporation where he held various positions of increasing responsibility in finance and accounting. Mr. Dallas holds a B.S. in Finance from the University of Tennessee, Knoxville.

  • Nikhil Mehta, Ph.D.


    Nikhil Mehta, Ph.D.

    Nikhil Mehta brings to AVEO more than 25 years of experience in the biotechnology and pharmaceutical industries, having played a key role in the development and approval of important therapeutic products in the areas of oncology and orphan disease. Prior to joining AVEO, Dr. Mehta served as Executive Vice President and Chief Regulatory Strategist at Tang Capital Management, where he played a key role in the establishment of two biopharmaceutical companies, Odonate Therapeutics and Sentier Therapeutics. Prior to Tang Capital, Dr. Mehta served as Global Head of Regulatory Affairs at Baxalta, a period during which the company gained approval for ADYNOVATE®, VONVENDI®, and OBIZUR. Prior to Baxalta, he was Vice President, Global Regulatory Affairs, Oncology, Hematology, Immunology and Diagnostics, at Merck & Company, where, among other accomplishments, he played a key role in the rapid development and first approval of Merck’s blockbuster checkpoint inhibitor, KEYTRUDA. Prior to Merck, Dr. Mehta held positions of increasing responsibility within regulatory affairs at Shire HGT, ImClone Systems, Bristol-Myers Squibb and Hoffmann-La Roche, where he played key roles in the approvals of ELAPRASE®, VPRIV®, FIRAZYR® and ERBITUX. Dr. Mehta holds a Ph.D. in Chemical and Biochemical Engineering from Rutgers University.

  • Emile Farhan, Ph.D.


    Emile Farhan, Ph.D.

    Emile Farhan has more than 20 years of experience in the pharmaceutical industry. As the Vice President of Technical Operations, he leads all aspects of chemistry, manufacturing and control of AVEO programs. He joined AVEO in April 2012 after his tenure at Eisai, where he served as the Head of CMC Global Operations Coordination for the US and Europe and as the Director of Pharmaceutical Development at MGI prior to its acquisition by Eisai. Prior to MGI, he served as the Senior Director of Product Development and Manufacturing at Mersana Therapeutics. Dr. Farhan also held several leadership roles at Pharm-Eco from 1992 until its acquisition by Johnson Matthey in 2000 and at Johnson Matthey Pharma from 2000 to 2006, where he was the Senior Director of Technical Operations and Scientific Affairs. Dr. Farhan holds a Ph.D. from Brandeis University and an MS from the University of Massachusetts.

  • Mike Ferraresso


    Mike Ferraresso

    Mike Ferraresso currently serves as AVEO’s Senior Vice President, Business Analytics and Commercial Operations. Prior to joining AVEO, he served as Vice President, Commercial Operations at Verastem, Mr. Ferraresso also previously served as Vice President, Commercial at Infinity Pharmaceuticals where he was instrumental in designing the commercial strategy for duvelisib and chaired the joint commercial committee for the partnership. From 1998-2013, he served in sales and commercial operations roles of increasing responsibility at several biotechnology and pharmaceutical companies, including at AVEO, AMAG Pharmaceuticals, Critical Therapeutics, Praecis Pharmaceuticals, Ascent Pediatrics and Muro Pharmaceuticals. Mr. Ferraresso has extensive experience in commercial strategy including partnerships, development, pricing and field deployment models and has launched Oprapred™, Plenaxis™, Zyflo™ and Feraheme™. Mr. Ferraresso holds a BA degree in Economics from Assumption College.

  • Karuna Rubin, J.D.


    Karuna Rubin, J.D.

    Karuna Rubin serves as Senior Vice President and General Counsel of AVEO. Prior to AVEO, Ms. Rubin served as an Associate at Arnold & Porter, LLP and as Assistant General Counsel at Cenveo, Inc. She has extensive experience representing public companies in a variety of industries in securities, finance, mergers and acquisitions, litigation and other matters. Ms. Rubin received her A.B. in International Relations from Brown University and her J.D. from Columbia Law School.

  • Lisa Bruneau


    Lisa Bruneau

    Lisa Bruneau brings to AVEO more than 20 years of financial and public company experience in the life sciences industry. She joined AVEO in 2016 as the Vice President of Financial Accounting and Reporting and Treasurer. Ms. Bruneau joined AVEO from Synta Pharmaceuticals, where she served as Senior Director of Finance and Director of Finance since 2004, including the company’s initial public offering. Prior to Synta, Ms. Bruneau worked at Diomed and Acambis (formerly OraVax) where she held various positions of increasing responsibility in finance and accounting, including OraVax’s initial public offering. Ms. Bruneau holds a B.S. in Business, Accounting and Finance from Bridgewater State College and an M.B.A. in International Business from Suffolk University in Boston.

  • Valerie Legagneur


    Valerie Legagneur

    Valerie Legagneur brings 20+ years of clinical research experience to her role as AVEO’s Vice President of Clinical Operations.  Prior to joining AVEO’s management team, Ms. Legagneur led up the Clinical Operations group as Vice President, Clinical Operations at Odonate Therapeutics Inc. Ms. Legagneur also worked at Pfizer Inc. for 10+ years in various roles of increasing responsibility within Development Operations.  In her last role at Pfizer she served as the Director, Clinical Operations Program Lead for the Hematology / Oncology Portfolio.  During her time at Pfizer she led several Clinical Operations teams that supported the clinical trial executions leading to approvals for IBRANCE™ and BESPONSA™.  Ms. Legagneur received both BA and MA degrees from State University of New York at Stony Brook.